Erick Gamelin insider trades
Open-market stock purchases and sales by Erick Gamelin, Chief Development Officer at Acrivon Therapeutics, Inc, from SEC Form 4 filings since Nov 14, 2022.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| May 18, 2026 | ACRV Acrivon Therapeutics, Inc | Bought (not open market) | — |
| May 14, 2026 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $776 |
| Mar 1, 2026 | ACRV Acrivon Therapeutics, Inc | Bought (not open market) | — |
| Feb 14, 2026 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $768 |
| Nov 14, 2025 | ACRV Acrivon Therapeutics, Inc | Sold (not open market) | $903 |
Companies traded
- ACRV Acrivon Therapeutics, Inc: other filings, last May 18, 2026